Santen launches its own Subsidiary in Italy
16 October 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced its new wholly owned subsidiary in Italy...
List view / Grid view
News
Roche delivers solid sales growth for the first nine months of 2014
16 October 2014 | By Roche
Roche announce Q3 2014 results...
Public-private partnerships vital to advance Ebola treatment pipeline, says GlobalData Analyst
16 October 2014 | By GlobalData
In the battle against Ebola, incentives from governments and healthcare policymakers have been and will continue to be vital for advancing the current treatment pipeline, by mitigating the risk and up-front costs from pharmaceutical companies, says an analyst with research and consulting firm GlobalData...
FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States
16 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States...
Coulter Partners further strengthens its activities in Europe
15 October 2014 | By Coulter Partners
Coulter Partners, the Global Life sciences search specialist, is delighted to announce the appointment of Tobias (Toby) Ernberg as Executive Vice President...
Promethera Biosciences receives approval in Belgium to enroll patients in the imminent HEP002 Phase IIb/III clinical trial
15 October 2014 | By Promethera Biosciences
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients...
Auspherix and Domainex announce collaboration to develop new drugs to treat antibiotic-resistant bacterial infections
15 October 2014 | By Auspherix & Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
Government-backed generics limiting Netherlands’ pharmaceutical market growth, says GlobalData
14 October 2014 | By GlobalData
The Netherlands’ pharmaceutical market value will rise slowly from approximately $6.7 billion in 2014 to $7.2 billion by 2020, with growth restricted by the government’s focus on generic drugs as a cost-containment tool, according to research and consulting firm GlobalData...
Imaxio signs an option for a license agreement with the German Cancer Research Center (DKFZ)
14 October 2014 | By Imaxio
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus (HPV)...
Pharmalink elects Bengt Julander as chairman
14 October 2014 | By Pharmalink
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has elected Bengt Julander as Chairman of the Board of Directors...
New findings from the Psoriasis Longitudinal Assessment and Registry (psolar) show persistency difference among biologic therapies
14 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than anti-TNFs in treatment of psoriasis according to observational study analysis...
New Oncology and Gustave Roussy announce collaboration on genetic testing
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
Rigontec GmbH raises €9.45m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
Cardio3 Biosciences receives authorization to enroll patients in Switzerland in its Phase iii clinical trial CHART-1
14 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Switzerland...
BioVigilant introduces Instantaneous Microbial Detection for pharmaceutical water monitoring
14 October 2014 | By Azbil BioVigilant
Azbil BioVigilant, inventors of Instantaneous Microbial Detection™, announced the introduction of its new IMD-W™ rapid microbial detection system for real-time water monitoring of pharmaceutical water sources...
